Market Overview

Stifel Nicolaus Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $205

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for JAZZ

DateFirmActionFromTo
Aug 2018BMO CapitalMaintainsOutperformOutperform
Aug 2018Stifel NicolausMaintainsBuyBuy
Jul 2018Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (JAZZ)

Jim Cramer Weighs In On Canopy Growth, FMC Corp, Vivint Solar And More

A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Earnings